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In recognition of 10 years of 
stem cell research at Yale, we 
have devoted this issue’s fea-
ture section to the Yale Stem 
Cell Center. Elsewhere in the 
magazine, you’ll find stories 
about ways in which our fac-
ulty, residents, and alumni are 
advancing medicine or explor-
ing history. 
Observing teenagers’ obses-
sion with video games prompted 
Lynn Fiellin, M.D. ’96, HS ’00, to 
wonder whether she could har-
ness that fascination to impart 
messages about health behav-
ior. Working with researchers, 
designers, educators, and  
community partners, she has 
developed a game that puts  
a virtual character into risky 
situations involving HIV, tobacco, 
and drug use.
By the time he got to medical 
school, Eliezer Sternberg, M.D., 
had already written two books 
about the mind. Now the first-
year resident at Yale New Haven 
Hospital has written a third, 
about how behavior that might 
seem strange to most of us can 
make perfect sense to others. 
“Our brain is always trying to 
create a narrative of our lives,” 
says Sternberg. 
Hair, writes Kurt Stenn, M.D., 
a pathologist and dermatolo-
gist who spent 20 years on the 
School of Medicine faculty, has 
affected culture, psychology, 
and even global trade. When the 
European beaver population was 
decimated to meet the demand 
for beaver hats, European 
explorers and trappers crossed 
North America in search of the 
pelts. In his book, Hair, A Human 
History, Stenn starts by explain-
ing why humans alone, of all 
primates, shed their body hair.
These and other stories await 
you in Yale Medicine. We hope 
you enjoy this issue.
John Curtis 
Editor, Yale Medicine
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  A decade of stem cell  
research at the School of Medicine
GE R M A N B IOL O GI S T S first named and described stem cells late in the 
19th century. More than 100 years later, scientists continue to rely on 
these cells to unlock puzzles of the origins of human development and to 
advance clinical treatment for diseases that were once considered incur-
able. A decade ago, the Yale Stem Cell Center opened its doors to pursue 
that field of research. 
Yale Medicine spoke with Dean Robert J. Alpern, M.D., Ensign Professor 
of Medicine, about the importance of human stem cell research and why 
much in the field remains to be explored.    
Why did you decide to open the Yale Stem Cell Center in 2006? Stem cells represented  
a new area in biology with extraordinary potential to transform medicine. Under-
standing human embryonic stem cells has provided insights into many areas of  
biology, including development, tissue regeneration, and cancer. It is too early to 
know the full impact that understanding stem cells will have on medical care, but 
progress has been impressive.
Why is it important to study stem cells? Stem cells have enormous potential to replace 
damaged tissue. Research on stem cells provides insight into development and 
developmental anomalies. In addition, we are now learning that with many cancers, 
it is the stem cells that are the real culprits.
Which aspect of stem cell research do you see changing most rapidly in the next five years?  
There will be continuing progress on many fronts. We must perform high-quality 
research that leads to a thorough understanding of the biology of stem cells so that 
they can be used therapeutically with maximal efficacy and safety. 
Stem cell research became politicized early on, partly due to the use of human embryos. 
Have we moved past the politics? If not, how can we? I am not sure that we have moved 
past the politics. There will always be ethical issues related to human embryonic 
stem cells and we must pay careful attention to these concerns. We should also keep 
dialogues open across a diverse group of individuals, from physicians to bioethicists 
















N I N E T Y-S E V E N PE RC E N T OF YOU NG A M E R IC A N S—
including the five children of Lynn E. Fiellin, M.D. ’96, 
HS ’00—play video games. According to the Entertainment 
Software Association, the industry’s top trade group, 
155 million Americans play video games with names like 
Call of Duty, Grand Theft Auto, and Madden NFL 15. What 
if, thought Fiellin, associate professor of medicine (general 
medicine) and in the Child Study Center, she could har-
ness that fascination with video games to teach adolescents 
to avoid risky behaviors that could lead to HIV infection or 
drug addiction?
  Better health  
 through video games
»
While there is a long-standing 
debate about the negative 
effects of video games (they’re 
sedentary, they encourage 
obesity, they can be addictive), 
the use of games to promote 
health is growing. Studies have 
shown that video games can 
deliver health promotion and 
interventions, and pharma-
ceutical companies, nonprofits, 
foundations, and the National 
Institutes of Health are explor-
ing these possibilities. With a 
yalemedicine.yale.edu4
grant from the National Institute 
of Child Health and Human 
Development, Fiellin has assem-
bled a team of researchers, game 
designers, community part-
ners, and educators to create 
PlayForward: Elm City Stories. 
The tablet-based game consists of 
16 hours of play in which teens 
in after-school, school-based, 
and summer programs create 
a virtual character who faces 
risky scenarios—like taking a 
relative’s prescription pills—to 
explore possible outcomes based 
on their actions and how those 
actions might affect their future. 
Elm City Stories, along with 
three other games designed to 
prevent tobacco and marijuana 
use, HIV infection in young 
women, and substance abuse in 
teens, emerged from the lab that 
Fiellin created in 2009. play-
2PREVENT (p2P)
Now, Yale has launched the 
Center for Health & Learning 
Games, which will will house 
the p2P lab and partner with 
departments across the uni-
versity and organizations 
nationwide to create and test 
additional games aimed at 
changing health behaviors and 
improving science, math, and 
other skills. The center will also 
offer training in game design 
in these areas. “While other 
schools have programs for devel-
oping games, this is the first I 
know of at a medical school and 
the first, I believe, that’s trying 
to fuse best practices for learn-
ing games and games for behav-
ior change, which are often 
found in separate silos,” said Ben 
Sawyer, co-founder of the game 
consulting firm Digitalmill and 
a pioneer in the field of “serious” 
games—games designed for pur-
poses other than entertainment. 
Marientina Gotsis, co-founder 
and director of the University 
of Southern California Creative 
Media & Behavioral Health 
Center, a research unit between 
the School of Cinematic Arts 
and the Keck School of Medicine, 
said that although some aca-
demic collaborations have pro-
duced games in health in the 
past eight years, none have led 
to the creation of formal centers 
or research units.
chronicle
Although newly established, 
the center’s work is well under-
way. Fiellin and deputy direc-
tor Kimberly Hieftje, Ph.D., 
associate research scientist in 
medicine (general medicine), 
have established partnerships 
with pediatricians, emergency 
room physicians, obstetrician/
gynecologists, and others. The 
center is collaborating with Yale’s 
math department, educational 
games developer Yogome, and 
Amplify, an educational services 
company that is testing learn-
ing games in India in collabora-
tion with The Global Education 
& Leadership Foundation. The 
center is also partnering with 
Peer Health Exchange, a national 
organization that teaches health 
education to high school students, 
to conduct implementation pilot 
studies to examine the integra-
tion of the game into their curric-
ulum. In addition, Fiellin and her 
team will work with the Tobacco 
Centers of Regulatory Science 
(TCORS) at Yale and at USC, 
modifying their PlayForward 
game to collect data from teens 
on their attitudes, perceptions, 
and knowledge of e-cigarette and 
other tobacco product use.
The center grew out of Fiellin’s 
conviction that there is a need 
both for games that foster learn-
ing and behavioral change and 
for research that shows that this 
approach works. It’s not enough 
to develop a creative game with 
educational content, as Fiellin and 
her team found out when they 
created Elm City Stories. They 
hired a leading game design firm, 
Schell Games of Pittsburgh, Pa., 
to help them develop the game. 
While the partnership was suc-
cessful from the start, both sides 
found it challenging to develop a 
game that would engage players 
and spark behavior changes that 
would lead to a reduced risk of 
HIV infection. So they drafted a 
series of game playbooks, guide-
books that incorporate estab-
lished psychological theories 
into the gameplay. For example, 
minigames—games within the 
larger game—encourage players 
to consider their future goals and 
aspirations, learn to assess situ-
ations and think ahead, acquire 
knowledge (like debunking the 
myth that you can’t get preg-
nant the first time you have sex), 
navigate peer relationships, and 
prioritize in order to maximize 
long-term benefits. “Our work 
is very much based in science,” 
said Fiellin. “Just like any science 
project, you need a lab manual to 
help you get a good result.” Now 
they use this approach for all of 
their games, which they then test 
in randomized controlled tri-
als. “There have to be some data 
behind this,” noted Fiellin. “You 
wouldn’t want your child taking a 
medicine that hasn’t been tested.”
The Yale center will build and 
test prototypes and then present 
Lynn Fiellin and a team of 
researchers, designers, 
community partners, 
and educators have  
created a video game 
that will help teens 
learn to navigate risky 
scenarios like drug use. 
Research shows, says 
















Since 2011, school 
faculty and administra-
tors have tried to make 
things a little easier 
for young scientists 
with a Junior Principal 
Investigator Retreat that 
helps them build their 
organizational skills.
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 




behavior has its logic
Schizophrenics who hear voices. 
An otherwise rational teacher 
who insists she was abducted 
by aliens. A woman with multi-
ple personalities. 
Most of us, including many 
physicians, would consider these 
people “crazy.”
Eliezer J. Sternberg, M.D., a 
fi rst-year neurology resident at 
Yale New Haven Hospital, begs to 
differ. Th eir behaviors may 
be strange, but they are not 
necessarily illogical, Sternberg 
wrote in his recently published 
book, NeuroLogic: Th e Brain’s 
Hidden Rationale Behind Our 
Irrational Behavior.
“A lot of Oliver Sacks-type sto-
ries seem so crazy on the outside,” 
them to game developers for 
fi nal full development, in much 
the same way that biotech com-
panies manufacture drugs and 
devices developed in academia. 
“It will be a research and pro-
totyping factory rather than a 
full-fl edged game factory,” said 
Sawyer, who has worked with 
Fiellin since the beginning.
Th e center will also provide 
increased training around game 
design as a structured educa-
tional experience. Th e p2P lab, 
which will be incorporated into 
the center, has already worked 
with more than 25 interns and 
trainees, ranging from high 
school students to postdoctoral 
associates. Th ese activities will 
be expanded, and discussions are 
underway to develop classes on 
the psychological constructs of 
games as well as other topics.
Using technology to improve 
access to care—especially with 
such hard-to-reach groups as 
adolescents is a powerful concept, 
according to Linda C. Mayes, 
M.D., Arnold Gesell Professor in 
the Child Study Center, who has 
worked with Fiellin on adapting 
games for children. Access to 
games that are well constructed 
and engaging may be better yet. 
“Playing a good game is like read-
ing a good novel,” said Hieftje. 
“It can have a lasting impact.”
—Jill Max
Strange behaviors may not be illogical, 
says Eliezer Sternberg, a fi rst-year neurology 
resident. His new book explains that a 
damaged brain may compensate in ways 
that seem logical to the patient, if not to the 

















snatched from his studies. “I am 
good at doing a lot with a very 
little amount of time without los-
ing momentum,” he said. 
The book was released in early 
January by Pantheon with a print 
run of 25,000 copies and has been 
reviewed in The Washington Post.
After completing his train-
ing, Sternberg, who dedicated 
his book to his wife, Sharona, 
and their 2-year-old son, Alex, 
wants to go into practice and do 
research. He also plans to write 
more books, possibly about epi-
lepsy or comas. 
Physicians should speak 
more often to a popular audi-
ence to prevent the spread of 
such dangerous misinformation 
as unfounded fears about child-
hood vaccines, Sternberg said. 
“People in medicine are really 
good at talking to each other 
but not as good at talking to the 
general public,” he said. “I think 
that’s a big problem, because 
some of the biggest speakers on 
medical issues have no medical 





For those who think the current 
U.S. mental health care system 
passes muster, Joel Roberts pro-
poses this question: “Do we tell a 
patient with stage 2 cancer to wait 
and come back when it’s stage 4?” 
When a mental illness led his col-
lege student son to the emergency 
of self. What appears delusional 
is the brain’s way of compensat-
ing for a deficit or illness, he said. 
“Our brain is always trying to 
create a narrative of our lives and 
give us a story, give us a history, 
give us a purpose,” Sternberg said. 
The 28-year-old Sternberg 
has been fascinated by the brain 
his entire life. NeuroLogic is 
not his first book. The Buffalo, 
N.Y., native had already written 
two volumes on the mind, the 
first when he was a 17-year-old 
high school junior, the second 
as an undergraduate at Brandeis 
University. 
Driving him is the ques-
tion of how a mere collection of 
cells—the human brain—can have 
consciousness and autonomy. 
“We are all made up of the same 
matter that everything else 
is,” Sternberg said. “But human 
beings are the only collections of 
matter that reflect on their own 
existence. What is it that makes 
that possible?”
He wrote the first three chap-
ters of what became NeuroLogic 
during a gap year he took from 
Tufts University School of Medi-
cine to do research. Inspired 
by the popular economics book 
Freakonomics, Sternberg wanted 
to write a book for a general audi-
ence that didn’t shortchange the 
science of the brain. To his sur-
prise, several publishers loved his 
proposal. Once he had settled on a 
publisher, Sternberg finished the 
book in his last year and a half of 
medical school. How did he do it? 
By composing most of the book 
in 10- to 15-minute increments 
he said. “But often, if you find 
out exactly what the defect is, 
exactly the brain problem, it’s 
almost as if their behavior is a 
logical compensation for a really 
unfortunate circumstance.”
Take schizophrenia. Hearing 
voices is the ultimate in irratio-
nality, but schizophrenics don’t 
recognize the voices in their 
heads as their own, Sternberg 
said. Faced with the irrational, 
their brains draw a logical, if false, 
conclusion: The voices are those of 
the FBI, or God, or aliens. 
“How would your brain explain 
that to you?” Sternberg said. “If 
you are the kind of person who is 
paranoid about the government, 
then government paranoia might 
overtake you. That would make 
sense to you and give you closure.”
Schizophrenia is just one of 
many neurological disorders or 
phenomena—both mundane and 
unusual—that Sternberg explains 
in his book. He tackles everything 
from why we forget to buy milk 
on the way home and whether 
visualizing golf improves your 
score to whether someone can 
be hypnotized to commit mur-
der and why people believe in 
alien abductions. Along the way, 
Sternberg discusses such obscure 
and unusual disorders as Anton’s 
syndrome, in which blind people 
do not realize they have gone 
blind. He explains how the dam-
aged brain compensates in ways 
logical to the sufferer, if not to the 
rest of us. 
A second theme is the mind’s 
relentless striving to make sense 
of the world and maintain a sense 
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room, Roberts, of Fairfi eld 
County, Conn., researched treat-
ment options across the country. 
Roberts, whose name has been 
changed to protect his family’s 
privacy, found that most programs 
targeted patients in severe, pro-
longed crisis.
According to Vinod H. 
Srihari, M.D., associate professor 
of psychiatry, few people receive 
timely treatment after their fi rst 
episode of psychosis. Th e rea-
sons can include a combination 
of factors related to the patient 
or the family’s awareness of a 
need for care, how to access 
professional care, and a lack of 
youth-oriented services.
Srihari wants to change 
these norms. “Patients may 
lack insight into their need for 
treatment, or, as is common to 
many youth, make poor choices 
around seeking help,” he said. 
He believes that savvy market-
ing via mass and social media 
channels could help. Two teams 
at Yale and Harvard are testing 
this approach through a fi ve-
year clinical trial funded by the 
National Institutes of Health. 
Th e trial tests the ways in which 
patients are recruited: traditional 
referrals or a campaign that 
includes media messaging, pro-
fessional outreach, and a rapid 
response to calls for help. In 2014, 
the trial’s baseline year, both 
teams recruited via tried-and-
true referrals from mostly tradi-
tional clinical settings. 
Harvard Medical School’s 
Prevention and Recovery in 
Early Psychosis clinic serves as 
the trial’s control and continues 
to recruit through referrals. At 
Yale, Srihari’s team emphasizes 
early detection through adver-
tising—he hired a New Haven-
based marketing fi rm, Red Rock 
Branding, to pitch a local aware-
ness campaign on psychosis, a 
mental disorder that includes 
hallucinations, paranoia, and 
delusions. 
Th e opportunity pushed Red 
Rock’s founder, Glen McDermott, 
and his team into uncharted ter-
ritory. “Focusing on a small target 
population—100 of 400,000—that 
is confronting a confusing and 
sometimes scary set of experi-
ences that are often stigmatized 
presents a communication chal-
lenge beyond the usual marketing 
strategy,” McDermott said. Th e 
campaign, called Mindmap, tar-
gets women and men ages 16 to 35 
in the New Haven area who may 
suffer from psychosis. 
In February 2015, the Red 
Rock team launched mindmapct.
org, a website with a quiz 
designed to assess symptoms 
of psychosis. Anyone who sus-
pects they’re at risk can call for 
a free screening by professionals 
at Yale’s Specialized Treatment 
Early in Psychosis clinic. If they 
qualify, they can join the trial. 
McDermott collects metrics 
through the website, Facebook, 
and Twitter to determine how 
people arrive on the quiz page. 
When potential patients call for a 
phone assessment, the Yale team 
verifi es which channel led them 
to the hotline. Recently Red Rock 
began hiring “Mindmap activ-
ists” to help refi ne and deliver 
the message, McDermott said. 
Th is cadre will share their own 
mental health journeys at events, 
write blog posts, and lead local 
workshops about psychosis. 
Final results won’t be avail-
able for some time, but Srihari 
has noted a correlation. Since the 
campaign’s start, calls to the free 
screening hotline at Yale climbed 
to 150, a 65 percent increase 
over the baseline year. Of those 
evaluations, a total of 38 patients 
enrolled in treatment at STEP.
What excites Roberts, a volun-
teer advocate for Mindmap, is the 
campaign’s potential to reduce 
the stigma of psychosis. Roberts 
wants to rewind back to that dark 
night on the psychiatric ward 
with his son. “I wish he could 
have heard from doctors and 
nurses that these symptoms are 
normal for your illness,” he said. 
“What you are experiencing is 
normal, and you will get better.”
—Kathleen Raven
ONLINE EXCLUSIVES
On September 11, 2001, 
Melissa Th omas was 
a sophomore at West 
Point. Just over four 
years later she was at 
a forward operating 
base north of Baghdad. 
In January she told her 
story as part of a new 
lecture series, Student 
Voices.
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 
on our home page at 
yalemedicine.yale.edu.
Vinod Srihari believes that patients with psy-
chosis often don’t receive the treatment they 
need early enough. A new program will help 
determine if a savvy marketing plan will help.
yalemedicine.yale.edu8
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Infant girls at risk of autism, a Yale School of 
Medicine study has found, are more socially aware 
than at-risk infant boys—they pay more attention 
to people and their faces. This increased awareness 
was linked to milder social impairments later on and 
may provide increased access to critical social expe-
riences in early development. In the study, the first 
of its kind, 101 infants who have older siblings with 
autism and 61 infants with no risk of autism watched 
a video of a woman smiling and cooing while point-
ing to toys and making a sandwich. A team led by 
Katarzyna Chawarska, Ph.D., associate professor in 
the Yale Child Study Center and in the Department of 
Pediatrics, then tracked what the children looked at 
and for how long. Chawarska’s lab hopes to discover 
why girls have this social advantage.
In the last 10 years of his life, the English monarch suf-
fered from memory lapses, fits of rage, uncontrollable 
impulses, headaches, insomnia, and perhaps even 
impotence. According to a paper published in the 
Journal of Clinical Neuroscience, these symptoms may 
have come from too much jousting. Yale researchers 
studied Henry VIII’s letters and other sources of the 
time to document his medical history and events pos-
sibly related to his ailments. (He died in 1547.) Their find-
ings support the notion that traumatic brain injuries 
from jousting may have caused the king’s problems. 
Historians, said behavioral neurologist Arash Salardini, 
M.D., co-director of the Yale Memory Clinic and senior 
author of the study, point out that the king’s behavior 
changed after a 1536 joust when a horse fell on him and 
knocked him out. “It is intriguing to think that modern 
European history may have changed forever because 
of a blow to the head,” Salardini said.
People who take risks in their youth are more likely 
to continue taking risks when they’re older, accord-
ing to an analysis of more than 44,000 German 
citizens published in the Journal of Personality and 
Social Psychology. These findings, said Gregory R. 
Samanez-Larkin, Ph.D., assistant professor of psy-
chology and a co-author of the paper, suggest that 
risk taking could be a personality trait that remains 
stable throughout adulthood. Samanez-Larkin and 
colleagues at the Max Planck Institute for Human 
Development in Germany and the University of Basel 
in Switzerland studied subjects ages 18 to 85 who 
participated for 10 years in a cross-national study. 
People’s willingness to take risks, the study found, 
depends on both their age and the risky activity. 
The inclination to take financial risks remains steady 
until retirement age, while the willingness to trust 
people doesn’t change with age.
GIRLS AT RISK OF AUTISM  
MORE SOCIALLY AWARE 
DID A KNOCK ON THE 
NOGGIN DRIVE  
HENRY VIII BONKERS? 
AGING RISK TAKERS  
STILL TAKE RISKS
An anthropology professor’s curiosity has debunked 
a myth about the main course at a 1951 dinner at the 
Explorers Club in New York. The dinner in the Grand 
Ballroom of the Roosevelt Hotel—which included Pacific 
spider crabs, green turtle soup, and bison steaks—
boasted an entrée supposedly carved from the carcass 
of a 250,000-year-old woolly mammoth that had been 
preserved in glacial ice. Even some hungry explorers 
were skeptical—many thought it was an extinct giant 
ground sloth, Megatherium. By means of an explorer 
who missed the dinner, leftovers found their way to the 
Yale Peabody Museum of Natural History. Eric J. Sargis, 
anthropology professor and curator of mammalogy at 
the Peabody, along with Yale graduate students Matt 
Davis and Jessica Glass, and Gisella Caccone of the Yale 
Center for Genetic Analyses of Biodiversity, decided in 
2014 to analyze the cooked meat’s DNA through mito-
chondrial gene sequencing. The verdict? Neither mam-














































































a collection of recent  
scientific findings
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ON THE SECOND FLOOR OF THE YA LE STEM CELL CENTER  is a machine 
that Haifan Lin, Ph.D., the center’s director, likes to show to visitors.  is $1 million 
metal box can do overnight what less than a decade ago would have taken hundreds 
of scientists years to accomplish—sequence a human genome. Already, Lin says, this 
3-year-old machine is showing its age. Newer machines are even faster.
 e machine is crucial to the work to which Lin has devoted his life, the study of 
stem cells. A decade ago, when the Yale Stem Cell Center was founded, this new fi eld, 
“the ultimate frontier in biology and medicine,” offered untold promise in any number 
of areas. Stem cells could reveal the secrets of how human bodies develop in the womb. 
Learning more about how stem cells differentiate and become bone, muscle, and other 
tissues could yield clues to controlling diseases. Stem cells have been used to test new 
drugs before they’re tried out on patients. And stem cells could generate healthy new 
tissues and organs to treat disease without provoking an immune response.
Since its founding, the center’s scientists have transplanted biomedically engi-
neered lungs and tracheae made from stem cells into mice.  ey have sought cures for 
Parkinson’s disease in stem cell research.  ey have studied links between stem cells and 
stroke. Scientists are trying to use stem cells to create retinal epithelial cells. Research into 
cancer stem cells could yield a treatment that would stop the disease at its source.
 e potential of stem cells seems limitless, and the Yale Stem Cell Center is poised to 
pursue that promise.
 A decade of stem 












Haifan Lin believes that there is much to learn about  
the basic science of stem cells. When he launched  
the Yale Stem Cell Center a decade ago, he wanted to  
understand the development and biology of stem cells.  
“The inner working mechanisms of stem cells are still 
poorly understood,” he says.
by kathleen raven 
photograph by robert lisak
A chance  
to lead
Connecticut lawmakers’ decision to fund 
stem cell research reverberates today 
yalemedicine.yale.edu12

A chance to lead
On August 9, 2001, Milton Wallack 
listened on the radio as then-President 
George W. Bush announced plans 
to halt federal funding for certain areas 
of stem cell research. “I remember it 
all too well. I’ll never forget that date,” 
the co-founder of Connecticut Stem Cell 
Coalition said. A close relative had just 
been diagnosed with type 1 diabetes, 
a chronic condition in which the 
body’s immune system mistakenly 
attacks and destroys insulin-producing 
cells. Researchers thought stem cells 
could one day replace these lost cells.
yalemedicine.yale.edu14
Bush’s mandate—which forced scientists to rely on 
just a few existing human embryonic stem (ES) cell 
lines—threatened scientific progress. Researchers 
prize human ES cells because they are easy to grow  
in the lab, and have the potential to become almost 
any cell in the body. Wallack, now a retired dentist  
in Branford, but always an activist, felt something  
had to be done.
He met with Yale’s Diane Krause, M.D., Ph.D., pro-
fessor of laboratory medicine, cell biology, and pathol-
ogy, and Wesleyan University’s Laura Grabel, Ph.D., the 
Lauren B. Dachs Professor of Science and Society, two 
researchers thinking of working with human ES cells 
in the state at the time. Gradually, Wallack’s coalition 
expanded to include academics, lawyers, and politi-
cians. In 2005, Wallack asked Paul Pescatello, J.D., 
Ph.D., then president and CEO of Connecticut United 
for Research Excellence, an organization formed to pro-
mote bioscience in the state, to become co-chair of the 
Connecticut Stem Cell Coalition. Their goal? Convince 
the state to provide funding for human embryonic stem 
cell research. Pescatello, who now leads the Connecticut 
Business & Industry Association’s (CBIA) Connecticut 
Bioscience Growth Council (as well as the New England 
Biotech Association), agreed. “We wanted to make it 
clear that Connecticut would be a safe haven for stem 
cell research,” said Pescatello, a lawyer who became a 
lobbyist for the biopharmaceutical industry after he lost 
his brother to glioblastoma. 
Despite the controversy surrounding embryonic stem 
cell research, Pescatello believed that a bipartisan legisla-
tive coalition would support it. Working with business 
and economic development advocates, especially the lob-
bying team at the CBIA, Pescatello drafted the blueprint 
for what became Connecticut’s stem cell statute. At the 
time, only California and New Jersey had plans to provide 
state funding for human ES cell research. Massachusetts’ 
policymakers were debating the issue, but they faced 
pushback from the Roman Catholic Church, whose influ-
ence was decidedly less in Connecticut, Pescatello said. 
By 2005, Wallack and Pescatello along with their team 
were ready to take their legislation to the state capitol in 
Hartford. The proposed bill permitted human embryonic 
stem cell research and set aside state funding for it, but 
banned any activity related to human cloning.
perfect timing 
Around the same time that Wallack and Pescatello’s 
team of lobbyists were meeting with state lawmakers, 
newly appointed Dean Robert J. Alpern, M.D., Ensign 
Professor of Medicine, and Carolyn W. Slayman, Ph.D., 
Sterling Professor of Genetics, professor of cellular and 
molecular physiology, and deputy dean for academic 
and scientific affairs, asked a strategic planning com-
mittee where the School of Medicine should strengthen 
its research focus. “The medical school had faculty 
members—some of whom knew each other, some who 
didn’t—who worked with stem cells,” Slayman said. 
“But nobody would have looked from the outside and 
said, ‘Yale is a powerhouse of stem cell research.’  
It just wasn’t true at the time,” she said. The committee 
recommended creating a stem cell center. In 2005,  
a search began for the new center’s director.
Haifan Lin, Ph.D., then a professor at Duke 
University, stood out among potential candidates, 
Slayman recalled. While other medical schools had 
focused on disease-specific research, Lin suggested 
that the field had far more to learn about the basic 
biology of stem cells. “How can it be that at cell divi-
sion (in stem cells), one daughter cell keeps all of its 
potential, while the other starts off on a process of dif-
ferentiation?” Slayman said, her eyes widening at the 
memory of the tantalizing, yet incredibly basic science 
question that faced the burgeoning field at the time. 
Lin accepted the position. 
  Milton Wallack 
 “When we started 
this in 2004, people   
 thought I was crazy 
and they said,  
  ‘You’ll never get   
 this done.’
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By late spring 2005, the Connecticut legislature’s 
public health committee began reviewing the proposed 
stem cell legislation. That committee’s co-chair, state 
senator and now U.S. Sen. Chris Murphy, became  
the bill’s key champion, Pescatello said. Former Gov. 
M. Jodi Rell remembered very little resistance among 
lawmakers. “The bill was written and drafted about 
20 times, then scientific leaders came in to make their 
case, and we decided this was the course we wanted 
to take,” she said. “It was time to step out front.” On 
June 15, 2005, Rell signed the act into law. The law 
earmarked $100 million in state funding for stem cell 
research, at a rate of $10 million per year through 2015. 
Gov. Dannel P. Malloy recently extended stem cell 
research funding for $10 million a year through 2018. 
lasting impact
In 2015, researchers at the Georgia Institute of 
Technology looked at how state funding had affected 
stem cell research in the few states that had set aside 
a large chunk of money in the mid-2000s. The team 
compared California, Connecticut, Maryland, and 
New York. “In both California and Connecticut, state 
funding programs appear to have contributed to over-
performance in the field,” they wrote in Cell Stem 
Cell. Connecticut especially seemed to reap benefits. 
Approximately 67 percent of human ES cell-related 
articles published by researchers in the state acknowl-
edged state funding, according to the study. 
Essentially no scientists were studying human 
embryonic stem cells in Connecticut in 2001, and now 
more than 150 researchers are working on such proj-
ects with state funding, Wallack said. At Yale, more 
than 30 labs work on human ES cell research today. 
Both the medical school’s stem cell core labs and the 
University of Connecticut-Wesleyan University Stem 
Cell Core have relied on state funding. While Yale’s 
core labs provide embryonic stem cell culture, genomic 
analysis, and imaging services, the UConn core focuses 
on induced pluripotent stem (iPS) cell technology, said 
Marc Lalande, Ph.D., who has directed UConn’s Stem 
Cell Institute in Farmington since its opening in 2007. 
The result has been close collaboration among the three 
universities in ways that complement one another, 
Lalande said. “Since this is a state fund, we have had a 
A chance to lead
great collaboration. We have retreats once each semes-
ter,” he said. “Diane and Haifan are good friends.” 
In March 2009, President Barack Obama, by execu-
tive order, lifted some of the restrictions on federal 
funding for human ES cells. One year later, UConn 
scientists contributed four brand-new human ES cell 
lines to the National Stem Cell Registry maintained by 
the National Institutes of Health for use by all stem cell 
researchers. Lalande pointed to the creation of ImStem, 
a stem cell therapy biotech company founded at UConn, 
and continued collaborations with Alexion, a biotech 
that was started by a Yale professor that moved its 
headquarters back to New Haven earlier this year. 
Two years ago, the legislature approved a measure 
that moved the responsibility of distributing state stem 
cell research grants from the public health department 
to Connecticut Innovations, a quasi-public organiza-
tion that serves as a state venture capital fund and 
lender. The Connecticut Stem Cell Program has been 
renamed the Regenerative Medicine Research Fund. 
This change reflects a broader trend in science, and 
does not take away the focus from stem cell research, 
Wallack said. 
“When we started this in 2004, people thought I 
was crazy and they said, ‘You’ll never get this done,’ ” 
Wallack recalled. A self-described optimist who 
“always sees the glass 110 percent full,” Wallack has 
already set his sights on a concern that weighs on all 
stem cell researchers who rely on state funding in 
Connecticut: how to secure the next round of funding 
after 2018. /yale medicine
Kathleen Raven is an associate editor at Yale Medicine.
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One stem cell  
or many?
Parkinson’s disease once looked like a poster child for stem 
cell therapy. Researchers knew that the chronic illness 
started when cells that produced the neurotransmitter 
dopamine died. Without dopamine, such symptoms as mus-
cle rigidity and tremors emerged. As early as 1990, a team in 
Sweden transplanted dopamine-producing cells from human 
fetuses into the brain of a male Parkinson’s patient. Two 
months later, the patient’s right arm appeared less rigid, and 
he could sleep through the night, the researchers wrote in 
the journal Science. Transplanted brain cells, the trial showed, 
could reverse some of Parkinson’s hallmarks. Two more 
decades would pass before scientists found clues to suggest 
why the therapy worked. In the meantime, a reliable cell-
based therapy for Parkinson’s remains out of reach.
When D. Eugene Redmond Jr., M.D., professor of psy-
chiatry and of neurosurgery, began researching Parkinson’s 
in the 1980s, patients had only one main treatment option: 
a pill called levodopa, or l-dopa, which the brain converts to 
dopamine. The drawback? While effective early on, the drug 
eventually stops working, and can cause awful side effects 
like hallucinations. If a fresh supply of neuronal stem cells 
began replacing dopamine in a tiny midsection area of the 
brain, the symptoms could be eliminated and the disease 
could be considered cured, Redmond said. 
Thirty-five years ago, Redmond started his lab on the 
Caribbean island of St. Kitts. Overrun with vervet monkeys, 
the island provided Redmond access to primates that can 
develop Parkinson’s symptoms in ways that closely mimic 
symptoms in humans. The disease can be induced in mon-
keys by exposing them to the synthetic drug MPTP, a neuro-
toxin. It kills the dopamine-producing neuronal cells in the 
brain—humans exposed to the drug also develop Parkinson’s 
symptoms. In 1985, Redmond injected fetal dopamine neu-
rons directly into the monkeys’ brains and they improved. 
This evidence helped support clinical trials in humans that 
would come later, including the Swedish study. Those neuro-
nal cells, however, could not be grown in vitro, and the use of 
fetal tissue was and still is controversial. 
Redmond and his lab members then tried multiple 
types of stem cells to see which could work as well as the 
fetal tissue grafts. Recently, they tried induced pluripo-
tent stem (iPS) cells. These cells, derived from a monkey’s 
skin cell, can be reprogrammed to become stem cells, then 
turned into dopamine neurons and injected back into the 
same monkey. Researchers want to use iPS cells as therapy 
in humans because the body is less likely to reject what it 
recognizes as its own tissue. 
Some monkeys that received iPS cells got better, but 
not predictably or consistently. Redmond and colleagues 
wondered whether they’d missed a piece of the puzzle: Were 
they putting in the right type of dopamine neuron—the cell 
that they had been transplanting over the years? Or perhaps 
the transplanted cells were not receiving the correct sig-
nals—called growth factors—from surrounding cells. 
Genetic sequencing technology could help answer 
these questions. Historically, A9 dopaminergic neurons, 
the ones predominantly lost in Parkinson’s disease, have 
been grouped into a single cell class, said Montrell Demond 
Seay, Ph.D., associate research scientist in psychiatry, who 
works in Redmond’s lab. “If your transplanted neuronal 
stem cell is not the one doing the real functional heavy lift-
ing, then your replacement therapy will never work,” Seay 
said. With the help of Sherman Weissman, M.D., Sterling 
Professor of Genetics, and Jennifer Yang, M.D., Ph.D., asso-
ciate research scientist in genetics, Seay has sequenced 
about 200 neuronal stem cells from a single monkey. They 
extracted RNA from the A9 dopaminergic neurons and 
sent the material off for genetic sequencing. Next, a bio-
statistician will determine whether there are different A9 
neuron cell types. Seay’s goal is to sequence 1,000 neurons 
from five different monkeys. Seay hypothesizes that each 
A9 cell subtype is linked to a particular function, and there-
fore to different Parkinson’s symptoms. In the future, cell 
transplants may include only specific subtypes for a more 
targeted therapy, he said.
Redmond’s lab is also trying to determine which growth 
factors will guide the organization of neuronal stem cells 
once they are transplanted. If developmental cues are 
absent when neurons are transplanted into adult brains, 
cells may not reach their designated target area. So far, 
Redmond and his team have tested glial cell line-derived 
neurotrophic factor (GDNF) as a possible instructional 
guide for stem cells in monkeys. The stem cells took root in 
the brains of 10 monkeys, they found, but after 11 months, 
only a small number of cells had differentiated into adult 
A9 dopaminergic neurons. To alleviate or cure Parkinson’s, 
enough transplanted stem cells must survive to replace the 
original dopamine cells that have died and organize them-
selves within the right place.
Earlier this year, Redmond harvested eggs from the 
ovaries of 30 monkeys to use in another promising tech-
nique in stem cell research: somatic cell nuclear transfer. 
Redmond and his team will place the nucleus of a skin cell 
into an egg cell whose nucleus has been removed. The 
modified egg cell will receive an electric shock to make 
it divide and reproduce. Ideally, this single cell will form 
a blastocyst, which contains stem cells. After changing 
into the right type of A9 neurons, these cells could be 
implanted into the brain of the monkey that provided 
the skin cells. Since the cells would be immunologically 
matched to the donor, enough cells might survive, and the 
result would be a long-term cure. “A few human patients 
treated with fetal dopamine cells have recovered and 
stayed better for periods of 10 or 15 years. I think it’s fair 
to say that there is proof of principle that this strategy 
will work,” Redmond said. “Now we have to create exactly 
the right cell to do the job reliably and permanently.”
—Kathleen Raven
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What are stem cells?
Every human being begins as an embryo consisting of a 
small bundle of stem cells—cells that are born as blank 
slates, and, when they receive the proper signals, turn 
into the skin, hair, muscle, blood, and other tissues that 
make up the human body. These toti- or pluripotent 
stem cells start with the ability to become any type 
of cell, but as the human body develops, they take on 
specifi c tasks that narrow their ability to diff erentiate. 
Five days after a fertilized egg gives rise to an embryo, 
the embryo’s inner mass includes embryonic stem cells 
(ESCs), which can become any type of cell. As stem cells 
reach their adult or postnatal state, they are no longer 
toti- or pluripotent, but may still diff erentiate into sev-
eral types of specialized cells. 
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Embryonic stem cells
Embryonic stem cells are pluripo-
tent—they can become any type 
of specialized cell and reproduce 
indefi nitely. ESCs are created 
through fertilization but can also 
be created through somatic cell 
nuclear transfer: DNA from an 
adult cell, like a skin cell, is placed 
into an unfertilized egg whose 
own DNA has been removed. That 
new cell can become a blastocyst 
(a 5-day-old embryo), which then 
yields embryonic stem cells.
Adult stem cells
The term adult stem cells is a mis-
nomer—everyone from newborns 
to the elderly has these postna-
tal cells, which are also called 
somatic stem cells. They reside in 
the brain, eye, muscle, skin, bone 
marrow, blood, and liver, self-
renewing throughout an organ-
ism’s lifetime and creating new 
cells to replace old ones. Natural 
adult stem cells are multipotent—
able to turn themselves into 
several types of stem cells but not 
as many as embryonic stem cells.
Induced pluripotent 
stem cell
Scientists have learned to tweak 
adult stem cells, reprogramming 
them in the lab to make them 
similar to ESCs in their ability to 
diff erentiate. Induced pluripotent 
stem cell lines are adult stem 
cells that have been “walked 
backward” and are as pluripotent 
as ESCs but don’t require the 
destruction of an embryo. 
Both embryonic and induced pluripotent 
stem cells have been used for gene therapy 
and organ repair. At Yale, scientists have 
bioengineered vascular tissue using stem 
cells and are working with them to regen-
erate the lung and trachea. Cell-based 
therapies could lead to treatments that 
would repair injuries to the nervous system, 
and understanding human embryonic stem 

























Priests, presidents, and scientists have  
debated for years the medical benefits  
and moral dilemmas posed by stem cell  
research, with no clear consensus.
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Religion, politics, morality, and stem cells
It was standing room only 
in the auditorium in the Anlyan 
Center on April 3, 2003, when 
actor Christopher Reeve came to 
speak about stem cells. Famous 
for playing Superman on the 
screen, he lost the use of all 
four limbs after a horseback-riding 
accident in 1995, and had become 
an activist supporting human 
embryonic stem cell (ESC) 
research. In his talk at Yale, 
Reeve decried barriers to the ESC 
research that he believed had the 
potential to cure his condition. 
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“It’s morally irresponsible not to allow research to 
go ahead on all these fronts, with very strict ethical 
guidelines,” said Reeve. He would not live to see this 
area of research bear fruit. In October 2004, he died  
of cardiac arrest.
Not everyone agreed with Reeve, however. Ethical, 
political, and religious concerns have plagued stem 
cell research since at least 1998, when researchers in 
Wisconsin derived the first human ESC line. This area of 
science may not only involve the destruction of human 
embryos to harvest or test stem cells, but it also raises 
concerns about such issues as human-animal chimeras, 
cloning, and donor payment or consent. Yet stem cells 
hold promise for treating patients with amyotrophic 
lateral sclerosis, diabetes, spinal injuries like Reeve’s, or 
other devastating conditions. The result: years of pas-
sionate debate that has reached no consensus, leading 
to a patchwork ethical and legal status for the cells. In 
the United States, state stem cell laws range from out-
right bans to encouragement and funding. Federal law 
permits the research, yet does not fund experiments 
that involve embryo creation or destruction. Promising 
though it is, human embryonic stem cell research in this 
country has proceeded in fits and starts.
protecting the embryo & egg donor
The year that Reeve spoke, stem cell research in 
the United States was sputtering. Two years earlier, 
President George W. Bush had announced that due to 
concerns over embryo destruction, federal funds could 
fund research only on existing lines.
Though the term stem cell includes ESCs as well as 
other types of stem cells, including adult stem cells 
found in fully formed organs, concerns about embryo 
destruction have dominated the ethical conversation 
since stem cells first appeared in labs, recapitulating 
arguments about the personhood and moral status of 
the embryo. Is the common practice of retrieving stem 
cells from an excess fertility clinic embryo justifiable, 
though that embryo be destroyed in the process? Some 
say yes, if the knowledge gained could save lives. 
Others, like Daniel Sulmasy, M.D., Ph.D., a University 
of Chicago ethicist and former Franciscan friar who 
served on New York State’s stem cell ethics board from 
2007 to 2009, say human rights begin at conception.  
That view makes embryonic destruction unethical and 
proposes a moral distinction between letting embryos  
die naturally and destroying them in the lab. 
The creation of new embryos—a practice that made 
headlines in 2014 when Oregon researchers announced 
that they had created patient-specific ESCs via  
“therapeutic cloning” with human eggs—also troubles 
Sulmasy. Anyone who believes human life merits 
respect from conception to natural death, he says, 
should oppose the creation of new members of human-
ity just to use those lives. In this view, he says, “No 
good end could justify that means.”
Since the 1973 Roe v. Wade decision that legalized 
abortion, such embryo-centered ideas have influenced 
federal policy. A two-year moratorium on funding 
embryo research followed that Supreme Court case; 
even after the moratorium was lifted, no federal funds 
were forthcoming. In 1979, an Ethics Advisory Board, 
born of the newly established congressional National 
Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research, approved experi-
mentation on embryos up to 14 days postconception, 
when the primitive nervous system arises. But despite 
that recommendation, Congress soon blocked federal 
funding for such research. The 1995 Dickey-Wicker 
Amendment banned the use of federal funds for creat-
ing or destroying human embryos, a ban that remains 
in effect today. In August 2000, the Clinton administra-
tion published guidelines that would have allowed sci-
entists to use federal funds to buy cells extracted from 
unused frozen embryos. A year later, before funding was 
dispersed, President Bush overturned these guidelines 
with his landmark announcement. It pleased no one.
“Neither side liked Bush’s attempt at a compromise 
solution,” says Stephen Latham, J.D., Ph.D., director of 
Yale’s Interdisciplinary Center for Bioethics, who formerly 
served on Connecticut’s State Stem Cell Research Advisory 
Committee and who is now a member of Yale’s Embryonic 
Stem Cell Research Oversight Committtee (ESCRO). Those 
opposed to embryonic destruction thought the govern-
ment’s hands were unclean, Latham recalls. Those who 
supported ESC research pointed out that the existing stem 
cell lines were of poor quality. Advocates and patients like 
Reeve seethed, and scientists, urged on by the president’s 
Council on Bioethics, changed gears and sought non-
destructive ways to obtain useful stem cells. 
Although the federal government would provide  
no funding for the research, it did not ban it. Some 
states, like Arkansas, Indiana, and the Dakotas, did 
ban the research, while others, like California and 
23Spring 2016
Connecticut, established funding and advisory com-
mittees. “We had this very sharp debate, but nobody 
ever said ‘Let’s make this illegal,’ ” Latham says. 
Money figures, too, into donor ethics. Sulmasy and 
others worry that stem cell research or therapy could 
lead to coercive payments to economically disadvan-
taged women for their eggs—a concern that becomes 
more relevant in the wake of the 2014 therapeutic cloning 
achievement, which could lead to any number of patient-
specific ESC therapies. The National Academies of Science 
disapprove of paying egg donors, though the ethics board 
in New York State decided (after Sulmasy left) to approve 
such payment from public research funds.
stem cells without embryos
In 2007, there came a long-awaited game-changer: 
stem cells that didn’t require embryo destruction. 
Scientists in the United States and Japan had walked 
human adult skin cells back into an embryo-like state, 
creating induced pluripotent stem cells (iPS cells),  
a momentous discovery that changed the field. Nine 
years later, Latham says, researchers are doing more 
work with iPS cells, which are cheaper and easier  
to procure than ESCs.
Alas, iPS cells didn’t do away with the ethical issues. 
For instance, iPS experiments may make use of  
ESCs as gold-standard comparisons, which means 
embryo destruction.
Another line of research attempts to derive sperm and 
eggs from iPS cells. In 2012, a Japanese group achieved 
this science fiction-like result in mice, announcing that it 
had created functional sperm from mouse skin cells; the 
new sperm successfully fertilized an egg, which in turn 
gave rise to healthy offspring. Needless to say, the pros-
pect of doing such a thing in humans is unsettling.
Then too, iPS researchers soon faced new consent 
issues. A major regulatory shift came in 2009, when 
President Barack Obama revoked the Bush ban by 
executive order, reintroducing federal funding for the 
study of stem cells derived from excess IVF embryos 
(though not for their derivation). Stem cell research 
advocates praised the step. The Obama order, however, 
included strict criteria relating to informed consent. 
Were biological parents of donated embryos fully aware 
of what might become of their donation?
“Some of the lines that Bush’s NIH was willing to 
fund turned out not to have good consent behind them,” 
Latham says. New guidelines eventually banned fund-
ing for research on older cell lines derived from lab-
created embryos, admitting only those derived from 
fertility clinic extras. 
Early iPS cells derived from commercially available  
cell lines, too, are likely to have been done without 
donor consent—as with Henrietta Lacks, whose famously 
immortal cervical cancer cells became a cornerstone of 
modern biomedical research, though she never consented 
to their dispersal before her death in 1951. 
“There are ethical concerns about derivation of iPS 
cells,” says Sandra Alfano, Pharm.D., a co-chair of the 
Yale ESCRO since its founding in 2006. “This idea of 
review of provenance and whether there was adequate 
informed consent, that’s probably the biggest part of 
the job for ESCRO currently.”
Maurice J. Mahoney, M.D., J.D., the other co-chair, 
adds, “We now insist that people be asked, ‘Is it all 
right that a cell line that came from your body ends up 
around the world, in many laboratories, and may be 
sold, may end up in animal species, which means that 
animal research is going on with cells from your body?’ 
… We push those issues now.”
These days, according to Latham, the ESCRO gives 
extra attention mainly to research proposals that involve 
mixing human ESCs with animal embryos in such a way 
that the animal’s nervous tissue or its sex cells could be 
affected. This addresses unlikely but nonetheless preva-
lent public concerns that a mouse could be neurologically 
humanized in a way that could increase its suffering, or 
that one with altered gametes might escape, reproduce, 
and cause an unpredictable environmental effect. 
no escaping the ethical questions
Yale’s ESCRO observes its 10th anniversary this June, 
well into the era of stem cell clinical trials. Dozens 
are now underway, thorny issues notwithstanding. 
For any discussion of ethical restrictions on stem cell 
research must also take into account the human cost of 
such restrictions—something Reeve made clear in his 
talk at Yale. Millions could die, he said, while scientists 
look for a way to avoid the ESC moral quandary. 
“To say that we should just work on adult stem cells 
because we’ll get there [eventually], that’s not fair to the 
people who are suffering from diseases like ALS,” Reeve 
said. “We’re going to lose valuable time.”  /yale medicine
Jenny Blair, M.D. ’04, is a frequent contributor to Yale Medicine.
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Hair, mice, and how 
cells regenerate
The human body loses billions of cells every day, but its 
self-renewing supply of stem cells, which can become 
any type of tissue, continuously replace those lost cells. 
Researchers, however, understand little about how this 
regeneration is sustained. Valentina Greco, Ph.D., associ-
ate professor of genetics, of cell biology and of dermatol-
ogy, and principal investigator at Greco Lab, wants to get 
to the bottom of it. 
What enables normal tissue, which can harbor 
mutated cells, to continue to regenerate as healthy tissue 
and not become cancerous? Greco looks for the answer 
in hair follicle stem cells in their niche—the microenviron-
ment in which stem cells live. She studies them in the skin 
of live healthy mice.  
Greco and her colleagues Ann Haberman, Ph.D., assis-
tant professor of laboratory medicine and of immunobiol-
ogy, and David Gonzalez, M.H.S., a research associate at 
Yale’s In Vivo Imaging Facility, adapted two-photon fl uo-
rescence microscopy to visualize cells in live mice. Greco 
can tag the cells she wants to follow in fl uorescent trans-
genic mice, and track them throughout their life cycle. 
Observing these cells in their natural environment, Greco 
hopes to identify the choices and behaviors of stem cells 
that sustain normal tissue function even when mutations 
are present. 
A better understanding of normal cell regeneration 
could help researchers predict when something will 
go wrong. “We could capture the initiation of cancer 
and understand how it emerges from normal tissue 
growth,” Greco said. “This has tremendous 




As an anesthesiology resident in Boston, Laura Niklason 
watched as cardiac surgeons sought usable veins for 
bypass surgery. That’s when she began working on  
creating new blood vessels in the lab. Now, her work in 
tissue engineering has moved on to the lung and trachea.
by ashley p. taylor 
photographs by robert lisak
Organ in  
a bottle
Laura Niklason works to  
engineer organs as replacements  
for those that fail.
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Organ in a bottle
On the windowsill of Laura Niklason’s 
office is an unusual knickknack: 
a clear glass jar like a jug turned on its 
side with two cork-shaped stoppers 
along its top, thin protrusions on both 
ends, and, inside, a paper sailboat. 
A ship in a bottle. The boat, stuck 
in there, Niklason says, by a stir-crazy 
grad student late one night in the 
lab, is no miniature yacht. But inside 
bottles like these, called bioreactors, 
Niklason, Ph.D., M.D., the Nicholas 
Greene Professor of Anesthesiology 
and Biomedical Engineering, 
builds structures that trump the 
trickiest marine art project: blood 
vessels, windpipes, and lungs. 
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Niklason first had the idea to build organs in the lab 
when, during her time as an anesthesiology resident in 
Boston, she watched cardiac surgeons struggle to find 
transplantable veins for bypass operations: “We ought 
to be able to grow a new one,” Niklason remembers 
thinking. She also has a doctorate in biophysics, and 
was a postdoc in the lab of chemical engineer and  
biomedical engineering guru Robert Langer, Ph.D.,  
at the Massachusetts Institute of Technology. It was 
there that she grew her first blood vessels. 
She continued her vascular engineering research at 
Duke University and founded a company, Humacyte, 
to build replacement tissues for clinical use. It is now 
testing engineered vessels for use in hemodialysis 
patients. Since coming to Yale in 2006, Niklason has 
expanded her tissue engineering work to the lung  
and trachea. She has also been collaborating with  
the core labs of the Yale Stem Cell Center, where she 
has a secondary appointment. Stem cell technology 
touches every area of her research. Eventually, she 
hopes to use stem cells, which can differentiate into 
many tissue types, as the cellular materials for all  
of her engineered organs. 
“She’s an amazing inventor,” says Haifan Lin, Ph.D., 
the Eugene Higgins Professor of Cell Biology; professor 
of genetics; and of obstetrics, gynecology, and repro-
ductive sciences; and director of the Yale Stem Cell 
Center. “She’s a modern Renaissance woman.” 
a bioreactor
Niklason’s initial framework for engineering a replace-
ment artery was to take blood vessel cells from a patient 
or animal, culture them on a tube-shaped biodegradable 
scaffold, and then implant the engineered vessels into 
the same patient or animal. To avoid immune rejec-
tion, the idea was to “make an engineered artery just for 
that patient or just for that animal.” In the Langer lab, 
her attempts to grow an artery this way failed for two 
years—until she started pumping nutrient-rich  
liquid (called medium) through the vessel as it devel-
oped within the bioreactor, causing it to expand and 
contract as blood vessels do in the body. To set up a 
blood-vessel bioreactor like the one in Niklason’s office, 
a researcher takes a silicone tube, sews a scaffold of 
biodegradable mesh around it, and threads it between 
the glass container’s protruding ends. The researcher 
then pipettes a solution of cells onto that scaffold. As the 
cells grow around the tube, medium courses through 
it, strengthening the developing vessel. Other tubes 
for providing nutrients and gas exchange enter the 
bioreactor through the stoppers on top, and the whole 
thing is filled with medium and kept in an incubator 
to control the temperature and atmosphere. Making a 
blood vessel this way takes about two months. Near the 
end of the growth period, the silicone tubing is removed, 
and the vessel is suitable for implantation into the body. 
In 1999, Niklason reported in Science that by using this 
method, she had successfully implanted pigs with engi-
neered arteries made from their own cells.
At Duke, Niklason tried the same approach using 
vascular cells isolated from elderly patients, but ran 
into problems. Because the patients’ cells were old, 
they had limited lifespans—they stopped dividing 
and became difficult to grow. Additionally, the tis-
sues they spawned were not as sturdy as those derived 
from younger cells. Niklason tried using gene therapy 
to trigger a lifespan-increasing enzyme, with limited 
success. “The cells lived longer, but they didn’t make 
tissues that were mechanically more robust.”
Once at Yale, Niklason tried a new approach: dif-
ferentiating stem cells into smooth muscle cells (SMCs), 
a major component of blood vessels, and using them to 
create arteries. These newly differentiated human cells, 
unlike those from elderly patients, would be young 
enough to work. In 2008, her lab reported that it had 
created an engineered artery by differentiating bone 
marrow-derived stem cells into SMCs and then coaxing 
the cells to form a blood vessel as before.
Now her team is building arteries and other tis-
sues with induced pluripotent stem cells (iPSCs). These 
cells are created by taking such differentiated cells 
as skin cells and treating them with certain factors 
that convert them into stem cells. Since a skin biopsy 
is an easier and less painful procedure than bone-
marrow isolation, this method has clinical advantages. 
Eventually, Niklason hopes, a doctor could take cells 
from a skin biopsy, create patient-specific iPSCs, and 
then differentiate those iPSCs into the tissue types 
needed to make personalized replacement organs.
The technology is a few steps behind this vision, 
however. “We can differentiate the cells from stem cells; 
we can make smooth muscle cells fairly well,” says 
Niklason, “but not well enough such that they create 
arteries that are implantable and strong enough to func-
tion long term.”
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Organ in a bottle
  Laura Niklason 
 “Stem cell science has just exploded in terms  
of what we know over the last 20 years.  
  The building blocks and the tools that  
 we have at hand now are just so vastly different  
   from what they were even 10 years ago.
Down another avenue of research, however, Niklason 
realized that personalized organs weren’t always the 
best choice. Beyond the problem of old cells, which stem 
cell technologies could circumvent, there were the con-
straints of time. If you need a new blood vessel, Niklason 
says, “you probably don’t have the luxury of sitting 
around three or four months and waiting for me to grow 
you a new artery. We started racking our brains about 
how to solve this problem in such a way that we could 
make a universal artery.” Her solution was something 
called decellularization.
Our cells secrete proteins that form the scaffold on 
which they live and move—the extracellular matrix. 
Wash away the cells, and the scaffold remains; this 
washing step is decellularization. Niklason washed 
away the cells of her engineered blood vessels and 
implanted those decellularized arteries into animal 
models. The decellularized vessels, she found, worked 
as well as transplanted native blood vessels—and with 
no immune rejection. “I can take this tissue, and I can 
implant it into any human, and it won’t be rejected 
by the body because we’ve washed away the stuff that 
came from somebody else.” Furthermore, the vessels 
didn’t stay decellularized forever. Taking cues from 
the extracellular matrix, “cells from the patient  
infiltrate into this tissue and turn it into a living tis-
sue over time.” 
The hemodialysis graft that Niklason’s company is 
currently testing is one such decellularized blood ves-
sel. Hemodialysis grafts create a conduit between a 
vein and an artery in the arm into which large-bore 
needles can be inserted to transport blood to and from 
the dialysis machine. Such grafts are made with either 
a patient’s own vein from elsewhere in the body or 
from plastic, and they often fail. Phase III trials com-
paring Humacyte’s decellularized grafts to their plastic 
equivalents are slated to begin this year. “My hope is 
that we’ll be able to grow thousands of these tissues 
that can then go out to hospitals and be implanted into 
any patient who needs a replacement blood vessel of 
this type,” Niklason says. 
Niklason is also using decellularization to engineer 
tracheae (windpipes). Unlike blood vessels, which are 
flexible, the trachea—supported by rings of cartilage 
surrounding the airway—is designed to resist collapse. 
In Niklason’s engineered windpipes, which she has 
tested in rats and primates, that function is served by 
a metal stent on which the tracheal cells are grown. 
“We’ve got a stent-tissue composite,” she says.
The cells that Niklason cultures in order to make 
decellularized blood vessels or tracheae for patients 
come from organ donors, but Niklason would like to 
use stem cells instead. She envisions a “bank” of stem 
cells that could be differentiated into various cell types 
as needed. “If we had an infinite cell bank, that would 
be wonderful in terms of the reproducibility of the ves-
sels that we make,” says Niklason. 
more complex tissues
The decellularization strategy worked with blood ves-
sels and tracheae, Niklason says, because many of their 
functions come from their physical architecture, which 
remains when you strip away the cells. That is not the 
case with such complex tissues as the kidney, heart, 
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and lung, Niklason says. “Their function is derived 
from the cells that are there. … So if you strip the cells 
away you have no organ function.” 
It is for engineering and transplanting one such 
complex organ, lungs, into rats that Niklason is per-
haps best known. For that project, reported in a 2010 
Science paper, she also used the technique of decel-
lularization, but this time for a different purpose. 
Instead of trying to engineer the many branching 
airways and air sacs of the lung, she decided to take 
a donor lung, wash away the cells, and use it as a 
scaffold on which to regrow the recipient’s own lung 
cells in a bioreactor that both pumped fluid through 
the lung’s vascular system and used another pump to 
make the lung “breathe.” Then, the recipients were 
rodents, but the goal is, of course, to build customized 
lungs for patients.
To reach that goal, the Niklason lab is counting on 
iPSCs. The lung contains many “flavors of epithelium,” she 
says, and growing enough of those various cell types from 
lung tissue biopsies is difficult. Instead, she and her team 
are developing tools to differentiate them from iPSCs. 
It helps that her lab is right above the stem cell core, 
the labs that specialize in producing human embryonic 
stem cells and iPSCs. “We work with them constantly,” 
says Niklason. As Niklason’s engineering approaches 
turn more and more toward iPSCs, that collaboration is 
bound to continue.
“Stem cell science has just exploded in terms of what 
we know over the last 20 years,” says Niklason. “The 
building blocks and the tools that we have at hand now 
are just so vastly different from what they were even 
10 years ago.” Then, scientists had just figured out how 
to create iPSCs from mouse tissue. Now, Niklason is 
using them to develop personalized engineered organs. 
“It’s a very exciting time to be working in this area, and 
I feel very fortunate.” /yale medicine
Ashley P. Taylor is a freelance writer in Brooklyn, N.Y.
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cells, they grow as tiny spheres that don’t undo 
themselves when you transplant them,” said Rizzolo. 
Because these light-sensitive cells, which don’t work 
without physical contact with RPE, are trapped inside 
those tiny spheres, RPE cannot keep them alive.
Rizzolo and his team have developed a gelatin-based 
scaffold in which to suspend RPCs and present them to 
RPE as a flat sheet. So far, the scaffold has allowed his 
team to produce flat, sheet-like retinal tissue. 
The question now is, if researchers implant the 
retinal cells later in the progress of the disease, will 
they still slow it down or better yet, reverse it? “Those 
experiments are in progress,” Rizzolo says. 
Rizzolo’s team and physicians at the Yale Eye Center  
will try the procedure on a live pig who underwent retinal 
laser burns that simulate macular degeneration. After sur-
gery, the pig will undergo tests to reveal whether its eyes 
have resumed normal communication with the brain.
“If the signal gets to the visual cortex in the back of 
the brain, this will tell me that not only did I reinstate 
circuits in the retina, but those circuits are sending infor-
mation to other parts of the brain.” /yale medicine
Sonya Collins is a freelance writer in Atlanta, Ga.
Seeing begins with photoreceptors, the cells that con-
vert light into signals that the brain translates into the 
images that we see. Those photoreceptors’ lives depend 
on a layer of cells at the back of the eye called the retinal 
pigment epithelium (RPE). “You can think of RPE as a 
nurse that keeps photoreceptors happy and functioning. 
If RPE gets sick and dies, photoreceptors get sick and die,” 
said Lawrence Rizzolo, Ph.D., professor of surgery (gross 
anatomy) who also runs a lab in Yale’s Stem Cell Center. 
“It happens the other way, too. If photoreceptors die, RPE—
not having photoreceptors to interact with—dies, too.”
As part of their day-to-day operations, photorecep-
tors shed some of their light-capturing membranes and 
acquire new ones. RPE eats the discarded membranes, 
clearing them from the eye. “If that doesn’t happen, 
you get all this debris in the retina that isn’t degraded, 
and retinal diseases occur,” Rizzolo said. Those dis-
eases are some of the leading causes of blindness, 
including macular degeneration, diabetic retinopathy, 
and retinitis pigmentosa.
RPE’s critical role in maintaining the health of 
photoreceptors makes this layer of cells a potential tar-
get for treatment of these blinding diseases of the retina. 
Researchers in Rizzolo’s lab are using human embryonic 
stem cells to bioengineer RPE and retinal progenitor cells 
(RPCs). They hope one day to implant the cells and restore 
sight to people with certain types of vision loss.
Animal studies have shown that implanting stem cell-
derived RPE in the eye in the early stages of disease could 
replace host RPE and slow vision loss. But later in the 
disease, the procedure does not yield the same benefits. 
In order for RPE transplant to gain traction as a treatment 
option, Rizzolo says, it needs to be available to patients 
who have begun to lose some vision and are willing to 
take the risk of surgery. “Suppose you see okay now, and 
you’ll probably see okay for another 10 years, but then I 
told you things are going to get worse, and if this proce-
dure works, we’ll slow that down—but if it doesn’t work, 
you could go blind tomorrow because, after all, it is still 
surgery and a difficult one.”
That’s not the only challenge for Rizzolo and other 
researchers. As embryonic stem cells differentiate to 
become RPE cells, they need RPCs nearby to shepherd 
them through the process and vice versa. For full func-
tion of both tissues, they need to co-differentiate. 
To address this problem, Rizzolo is growing RPE 
cells on a matrix alongside retinal progenitor cells. He 
and other researchers still need to find a way to grow 
this retinal tissue in a flat sheet that mimics a normal 
human retina. “When you grow retinal progenitor 
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The promise of stem cells
Since their first therapeutic human 
use in 1957, when Seattle physician 
and future Nobel laureate E. Donnall 
Thomas, M.D., attempted a bone 
marrow transplant to treat leukemia, 
stem cells—those miraculous 
collections of cytoplasm and nuclei 
capable of an astonishing amount of 
cellular transformation—have offered 
to medical researchers, doctors, 
and the public alike the prospect 
of curing intractable diseases and 
crafting a storehouse of spare parts to 
remedy all manner of tissue damage. 
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In 2006, buoyed by a combination of $10 million from 
the State of Connecticut and $80 million in university 
funds, Yale created its own Stem Cell Center (YSCC) at 
the School of Medicine and recruited Haifan Lin, Ph.D., 
a rising superstar in the research community, to lead 
the fledgling effort.
“Ten years ago, we began the center with a vision for 
what we might be able to do with stem cells, both in 
terms of medical applications and helping resolve the 
mystery of life,” says Lin. “I’m happy to tell you that 
quite a lot has been achieved on both fronts.”
More than 89 research groups from 23 depart-
ments are gathered under the YSCC umbrella, and 
their interests run the gamut from deciphering the 
fundamentals of stem cell biology to developing the 
best ways of using the cells to treat some of the worst 
human scourges, cancer and heart disease among 
them. Working with the highest of high-tech tools in 
laboratories dedicated to genomics as well as to grow-
ing, imaging, and manipulating what Lin calls “the 
mother of all cells,” scientists here are beginning to see 
these investments pay off. They now have the ability to 
make custom-tailored tissues and organs that, because 
they’re made from an individual’s own stem cells, 
are transplantable with much less risk of the body’s 
immune system attacking them and causing rejection. 
“YSCC researchers have pioneered this approach 
to repair children’s broken hearts,” says Lin, high-
lighting work by Christopher K. Breuer, M.D., and 
Toshiharu Shinoka, M.D., who developed techniques 
in which stem cells harvested from the bone mar-
row of children born with heart ventricular or atrial 
defects could be reprogrammed to transform into new, 
fully functional blood vessels that were then used to 
repair the heart defects. (The two doctors now head the 
Tissue Engineering Program at Nationwide Children’s 
Hospital in Columbus, Ohio.)
this isn’t science fiction anymore
The first successful operation using such stem cell- 
engineered cardiac tissues took place five years ago at 
Yale-New Haven Hospital, and offshoots of the tech-
niques are under investigation to develop other replace-
ment parts, from sections of the brain to new lungs. 
“This isn’t science fiction anymore,” says Lin, noting that 
400,000 people die each year from lung disease because, 
to a large degree, “there aren’t enough donors.”
Much of this progress, however, would never have 
been possible were it not for a fundamental break-
through announced at the time the YSCC opened for 
business. In 2006, Japanese researchers demonstrated 
that such ordinary adult mouse cells as skin cells could 
be reprogrammed to become nearly as malleable as 
embryonic stem cells, and the same possibility was 
shown in human adult cells the following year. This 
discovery allowed researchers to work with stem cells 
that had not come from aborted fetuses, thereby avoid-
ing the fierce ethical and moral debates. The ability 
to now use induced pluripotent stem cells—iPSCs, for 
short—however, has given Yale scientists an almost 
limitless supply of raw material for applied and equally 
critical basic investigations.
reprogramming adult cells
The ability to reprogram an adult cell so that it func-
tions like an embryonic one is “incredibly cool,” says 
Diane S. Krause, M.D., Ph.D., the YSCC’s associate 
director who works with bone marrow-derived stem 
cells to understand their involvement in the develop-
ment of certain kinds of leukemia and how such cells 
might be used in therapies against cancer. 
Krause, a professor of laboratory medicine, cell 
biology, and pathology, explains that while iPSCs have 
yet to make a jump into a hospital setting, there are 
at least a couple of scenarios—gene therapy and organ 
repair—on the horizon. In advanced cases of sickle-
cell anemia, for example, doctors attempt to treat the 
condition with a bone marrow transplant that comes 
from a close relative of the sufferer. A cure is possible, 
says Krause, “but the patient is also very much at risk 
for graft-versus-host disease, which is serious and can 
be fatal. So what if you could take the patient’s own 
stem cells, correct the genetic defect that we know 
causes the disease, then induce them to make fixed 
copies that we could now transplant back? With such 
an autologous transplant, there would be little risk of 
graft-versus-host disease.”
In the case of a heart attack, adult stem cells from 
the organ could be induced to become, say, muscle 
cells that can be transplanted to regenerate new func-
tional cardiac tissue instead of the scarring that now 
typically results when an infarct leads to oxygen depri-
vation and tissue death. 
Another area in which stem cells could prove 
important involves the liver, particularly in the case 
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of accidental or deliberate acetaminophen overdoses, 
which can kill enough cells to prove fatal. “The liver is 
actually really good at regenerating,” says Krause, “but 
there are some patients who have a transient prob-
lem with liver regeneration, and if they could just get 
enough cells to function until their own liver restores 
itself, they would be able to survive long term.” 
An autologous transplant of iPSCs reprogrammed to 
become liver stem cells could, in theory at least, keep 
a patient alive long enough to enable the damaged 
organ to regain its functionality. All this, of course, 
is a promise for the future. “We know perfectly well 
that we can use iPSCs to treat acute liver failure,” says 
Krause. “But we don’t know how to make the cells 
become functional lymphocytes, how to get enough of 
them, and how to make sure they’re safe.”
the importance of basic research
That, says Lin, is where fundamental research comes 
in. “We realized early on that we didn’t fully under-
stand the inner workings of stem cells, and without 
the knowledge of the molecules that make them tick 
and make them quiet, we would never be able to har-
ness their power and come up with rationally designed 
therapies,” says Lin. “We’d just be guessing.”
Lin received his bachelor’s degree at Fudan University 
in 1982 in his native China, and a doctorate at Cornell 
in 1990. Starting in 1994 at the Duke University Medical 
School, Lin focused on a bold but risky research area:  
the vast stretch of the genome known as “junk DNA.”  
A small percentage of the human genome—some 26,000 
genes—is known to make messenger RNA molecules that 
help code for proteins, says the researcher. “The rest was 
considered useless,” Lin explained, “but that turned out 
to be more because of technological limitations than real-
ity. We just weren’t able to find where the genes were and 
how they might affect development in model species and 
in humans, so we dismissed them as unimportant.”
With improvements in molecular tools, includ-
ing such revolutionary technologies as DNA deep 
sequencing, a gene-editing method known as CRISPR, 
and others being used and developed in the YSCC 
core laboratories, Lin and others discovered that this 
viewpoint was akin to saying that since most humans 
lived in cities, the countryside no longer mattered. It 
turned out that this so-called noncoding stretch of the 
genome mattered plenty. “Junk DNA is making mil-
lions of little RNAs that are very important for deter-
mining the fate of stem cells—for turning them on and 
off at the right time,” Lin explains.
Learn to hit the start button effectively, and the 
result can be a supply of spare parts. Learn to hit 
the stop button, and the result might be the medi-
cal equivalent of the Holy Grail: an effective cure for 
cancer. “Studying stem cells is not only important in 
regenerative medicine,” says Lin. “We believe that the 
fundamental insights we’re discovering will turn out 
to be crucial in creating a kind of personalized medi-
cine that can treat malignancies.”
Current cancer treatment, of course, is brutal, since it 
can’t discriminate between actively dividing normal cells 
and their out-of-control counterparts. But Lin is work-
ing with some of his fundamental RNA insights on stem 
cell reprogramming and control to find medications and 
techniques to better diagnose and conquer breast cancer. 
Preliminary results from his lab suggest that the rogue 
cells responsible for metastatic disease can be stopped 
from migrating, and over the next decade, Lin feels that 
such studies may lead to the rational design of “very tar-
geted, much less harmful” therapies.
Stem cell research may point to something even 
more astounding. “We are on the verge of learning how 
to protect the genome from being damaged, and this 
might enable us to figure out how to extend a healthy 
life for a longer time,” says Lin, suggesting that “old age” 
may, sometime in the not-too-distant future, need to be 
redefined. “We’re very excited about the progress we’ve 
made and the prospects of what’s to come. The whole 
field is undergoing evolutionary change, and Yale is an 
integral part of it.” /yale medicine
Bruce Fellman is a freelance writer in North Stonington, Conn.
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Why do so few stem cells convert?
Nearly a decade ago, stem cell researchers learned how to 
create a cell that mimics a human embryonic stem (ES) cell. 
Today, scientists in labs routinely create what are called 
induced pluripotent stem (iPS) cells by reprogramming adult 
somatic cells. These iPS cells are prized because, like embry-
onic cells, they can become almost any cell type in the body. 
But in a sample of 1 million adult somatic cells, only about 
100, or 0.1 percent, will convert to iPS cells in the lab—a very, 
very low effi  ciency rate, said Shanqin Guo, Ph.D., assistant 
professor of cell biology. Researchers don’t know why this is. 
“If we understand the general rules of when and how one cell 
type changes into another then we should in theory, be able 
to interconvert any other cell types,” Guo said.
Guo and her team have amassed thousands of live micros-
copy images of mouse adult cells turning into mouse iPS 
cells. They’ve tracked converted iPS cells in reverse to detect 
patterns that might hint at certain qualities adult cells have 
before they convert to iPS cells. So far, Guo has found that suc-
cessfully converted iPS cells begin dividing more rapidly while 
they are still adult somatic cells. Now Guo wants to determine 
which comes fi rst: a mechanism that turns on in somatic cells 
allowing them to divide more rapidly, or an inherent ability to 
divide rapidly that activates a certain mechanism. After that 
conundrum is solved, the exact molecular mechanism that 
aids in iPS conversion might come into focus. 
—Kathleen Raven
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  Longest-running 
show on Cedar  
 Street ends after  
  more than 60 years
In 1949, William G. Anlyan, 
then a fourth-year med 
student, encouraged his 
classmates to poke fun at 
their professors and deans 
in a song and dance review 
called the “Four Years for 
What Follies.” Anlyan wrote 
the script, directed the 
show, and provided piano 
  Student spoof of life at Yale Med  
will re-emerge as a Fourth-Year Show
  By John Curtis
Class of 1996Class of 1980
Class of 1990Class of 1949
accompaniment. It was an 
outgrowth of the vocal quar-
tet (The Forceps, featuring 
Bi, Tri, Quadri, and Contra) 
he had formed previously. 
For the next few years most 
fourth-year classes main-
tained the new tradition, 
though some were too caught 
up in their coursework for 
such frivolity. By the 1960s—
the exact date is unclear—the 
scattering of fourth-years to 
clinical clerkship sites across 
Connecticut had made it dif-
ficult to produce a show. A 
second-year show marking 
the end of a pathology course 
took over as the main stu-
dent production.
That show endured until 
Saturday, Feb. 20, of this year, 
when the curtain fell on the 
longest-running production 
on Cedar Street. The intro-
duction of a new curriculum, 
which will have second-year 
students on clinical rotations 
at a time when the frenzy  
of producing the show  
kept them out of class for 
weeks in February, made this 
year’s show the last second-
year production. It is hoped 
that fourth-year students will 
carry on the tradition. 
As they prepared this 
farewell show, members of 
the Class of 2018 felt an obli-
gation to honor the tradition 
and those who have made it 
such a success over the years. 
”It influenced our whole 
plot,” said Robin Wu, one 
of the show’s co-directors, 
with Max Farina and Tejas 
Sathe. “It was important to 
acknowledge the tradition of 
the show,” added Farina.
This year’s show, 
“Remediation,” paid tribute 
to past shows through the 
travails of four stereotypical 
medical students (the nerdy 
scientist, the do-gooder, the 
legacy admit, and the shal-
low frat boy), all of whom 
had failed a qualifier in the 
history of medicine. Each 
incorrect response to the 
question, “What was the 
most important day in the 
history of the Yale School 
of Medicine?” sends them 
on a trip through history. 
Unbeknownst to them, 
Lawrence Rizzolo, Ph.D., one 
of their anatomy professors, 
has rigged their computer as 
a time machine. Their first 
stop takes them to medieval 
times, and an encounter 
with an early incarnation of 
Auguste H. Fortin VI, M.D., 
M.P.H., associate professor 
of medicine. “Medicine?” 
the medieval Fortin asks. 
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OPPOSITE PAGE Producers of the 
first student show, 1949’s fourth-year 
production, “Four Years for What Fol-
lies,” typed their program on stationery. 
Over time, the playbills became more 
polished and the show titles were 
not averse to puns and plays on other 
titles. The Class of 1982 evoked Samuel 
Beckett with “Waiting for Fallot,” a 
reference to a congenital heart defect. 
The popular Broadway musical comedy, 
A Funny Thing Happened on the Way to 
the Forum, inspired the Class of 1990. 
When the Class of 1996 produced their 
show, their playbill was designed to 
look like TV Guide and asked “Docs on 
T.V.? See p.2.” At the time, eight popular 
television shows, including ER, North-
ern Exposure, and Dr. Quinn, Medicine 
Woman, featured physicians. 
Class of 2000 Class of 2001
ABOVE, PROGRAMS The Class 
of 2000 took their title from a 
popular TV show of the 1990s, 
calling their production “The Rx 
Files.” The plot had Agents Mulder 
and Scully searching for the miss-
ing Cushing brain registry. James 
Bond was the inspiration for the 
Class of 2001’s “Live and Let Diag-
nose,” whose plot lines included 
human clones and Y-agra, a drug 
that compels medical students to 
attend class.
ABOVE, PHOTOS This spring, the 
Class of 2018 presented the last 
second-year show, “Remediation.” 
The plot had students traveling 
through time to milestones in the 
medical school’s history. Sophie 
Chung (top) played Harvey Cushing, 
M.D., in a scene called “Phantom of 
the Operating Room.” No second-
year show would be complete 
without a joke about the digital 
rectal exam (bottom). A hapless 
patient, played by Dharshan  
Anandasivam, assumes the 
position as Sam, played by Alyssa 
Mitson-Salazar, prepares to  
administer the exam during a  
“Doc Off” with “Darth Alpern.”
“Medicine is just conjecture 
and fraud. We are a highly 
respected institution: The 
Yale School of Magic!!”
The students continue 
through key moments of 
the 20th century, including 
the birth of modern neuro-
surgery, rock and roll, the 
civil rights movement, and 
the admission of the first 
African-American woman to 
the medical school.
The climactic scene,  
based on Star Wars, pits Sam 
(played by Alyssa Mitson-
Salazar) against “Darth 
Alpern” (played by Daniel 
Barson) in a “Doc Off” duel for 
the soul of the medical school. 
“Between the consulting gigs 
and all the talk of RVUs, it’s 
become so clear that medicine 
has become such a business,” 
Sam tells Darth Alpern. “And 
it seems that you’re doing a 
great job running that busi-
ness. But can we still call this 
doctoring?” 
In the end, Darth Alpern 
promises to hold a Town 
Hall on the subject and the 
students find their way back 
to Cedar Street. And the elu-
sive answer to the question, 
What was the most impor-
tant day in the history of the 
Yale School of Medicine?
“Where would Yale Med 
be today without every day?” 
asks Sam. “Without every 
moment? Without … .”
On a screen in the back-



















































One night last December, Scullers 
Jazz Club in Cambridge, Mass., 
was packed with national experts 
on child abuse, Peace Corps 
veterans, and book group buddies, 
all there to honor Eli Newberger, 
M.D. ’66, HS ’67, M.P.H., who sat in 
perhaps his favorite spot on Earth—
on stage, cradling his beloved tuba.
Newberger, a renowned child 
abuse expert as well as a fixture 
in Boston’s jazz scene, was turn-
ing 75 the day after Christmas. 
The club added a second show to 
accommodate fans of his medi-
cine and his music.
Kicking off an all-Gershwin 
set with his group, Eli & the Hot 
Six, Newberger told the crowd: 
“The amygdala in the brain is the 
center for our sensation of stress. 
It sets off a cascade of hormones 
and messages. This is also where 
music enters our brain.” Not your 
typical stage patter.
But then, Newberger’s not 
your typical musician or pedia-
trician. Both pursuits have been 
important to him throughout 
   From music to  
 medicine and back
»
A LIFELONG LOVE OF JAZZ and a desire to care 
for society’s most vulnerable children have 
sustained Eli Newberger throughout his career.
his life: In addition to establish-
ing himself as an expert on child 
abuse, he has released more 
than 40 acclaimed jazz albums. 
As a pediatrician, he’s testified 
in prominent cases of child and 
sexual abuse.
His path began at Yale College, 
where he started in physics before 
switching to music theory and 
taking pre-med courses on the 
side. By the time he graduated 
in 1962, he’d decided to apply to 
medical school and do music—
he’s played the tuba since he was 
10—on the side. He graduated,  
married Carolyn Moore, a flau-
tist from Sarah Lawrence, and 
the couple played with the New 
Haven Symphony Orchestra 
while he attended medical school. 
The two would continue to work 
together—for 30 years, the couple 
collaborated at Boston Children’s 
Hospital, where he was a physi-
cian chief and she was director 
of research and training in the 
Family Development Program.
After receiving his medical 
degree, Newberger completed an 
internship in internal medicine 
at Yale-New Haven Hospital. But 
the Vietnam War was raging, 
and male doctors were required 
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Throughout his life 
and career, music has 
sustained Eli Newberger 
and helped him relieve 
the stress of his work as 
a pediatrician who has 
offered his expertise in 
child and sexual abuse  
in high-profile criminal 
trials. He relaxes by play-
ing the tuba in his jazz 













to register for the draft. Th e 
Newbergers opposed the war, so 
he applied to become a doctor in 
the Peace Corps. In 1967, the cou-
ple moved to Upper Volta in West 
Africa—now Burkina Faso—with 
their 1-month-old daughter.
Newberger's stint in Africa 
included working with impover-
ished mothers and children, and 
led him to an interest in pedi-
atrics and a residency at Boston 
Children’s Hospital. As a resident, 
he alerted the physician-in-
chief about “a worrying pattern 
of rehospitalizations” of young 
patients who had been reported 
to child protective services. 
Mandated reporting laws for sus-
pected child abuse were new, and 
the hospital staff wasn’t yet well 
trained in recognizing such abuse. 
Newberger was asked to fi nd out 
what other hospitals were doing.
He was just 29 years old 
when he was asked to start a 
child abuse unit at Children’s 
Hospital. He had no experience 
in the fi eld, but Newberger’s 
multidisciplinary team of doc-
tors, nurses, and social workers 
would become a national model. 
In Boston, Newberger is best 
known as the key prosecution 
witness in the trial of Louise 
Woodward, the British nanny 
convicted of second-degree 
murder in the death of 8-month-
old Matthew Eappen in 1997. 
Newberger testifi ed that Matthew 
was the victim of violent pro-
longed shaking, and that a blood 
clot on his brain and a fractured 
skull indicated that he had also 
been slammed against a hard 
surface. Newberger also offered 
his expertise on the effects of 
abuse on children and their fami-
lies during the sex abuse crisis in 
the Archdiocese of Boston.
Today, the Newbergers are 
semi-retired from the health 
care fi eld, but perform with Eli 
& the Hot Six, in which Carolyn 
plays the washboard. Th ey have 
a second home in the Berkshires, 
where he writes music reviews 
for the online site Th e Berkshire 
Edge, and Carolyn, a gifted art-
ist, illustrates them. Th e booklet 
that accompanies the Hot Six’s 
new CD, “Contemporary Classic 
Jazz,” features Carolyn’s real-time 
sketches of the performers.
Th e nexus of medicine and 
music has sustained Newberger 
throughout his career. Starting 
in 1971, he and his band had a 
regular Th ursday night gig at a 
suburban Boston pub. It was the 
same year he started his Th ursday 
outpatient clinic, and he’d go 
directly from the hospital to the 
pub. “I had 30 years of stress 
overload that was compensated 
by performing jazz,” he said. “Th e 
positive sensations in experienc-
ing music are processed in the 
same midbrain organs as those 
that bring us to hyperalert in the 
face of severe danger. Th e music 
enabled me to do what’s most 
challenging—and for many physi-
cians in child abuse work—vexa-
tious, caring for the victims and 
their families, offending and 
unprotecting parents included.”
—Bella English 
Bella English is a reporter for The Boston Globe, 
where a version of this article fi rst appeared.
»
Pearls of wisdom from 
years on the wards
In the fall of 1960, Lewis 
Landsberg, M.D. ’64, HS ’70, 
fi rst set eyes on the legendary 
Paul Beeson, M.D., at a Saturday 
morning medical ground rounds. 
As Beeson entered Fitkin 
Amphitheatre, the renowned 
chair of internal medicine at 
Yale took his usual seat in the 
fi rst row on the right-hand 
side of the lecture hall. Th en 
the learning began with the 
clinical presentation of real 
patients, who were frequently 
in attendance. It didn’t take 
but a couple of months for 
Landsberg, then a fi rst-year 
medical student, to realize that 
he was no longer interested in a 
career in psychiatry.
“Internal medicine at Yale 
was exciting and compelling,” 
said Landsberg about his choice 
of specialty. “Intellectually 
challenging, it was an area of 
medicine I wanted to pursue.” 
And indeed he did—becoming a 
leader in his fi eld and reaching 
the highest ranks of academic 
medicine.
Landsberg’s leadership roles 
took him from Yale to Harvard 
and fi nally Northwestern, where 
he served as dean of the medical 
school. During almost half a cen-
tury of experience as a clinician 
and teacher, Landsberg distilled 
his knowledge into aphorisms 
to teach budding physicians 
the art and science of caring 
for ill patients. He often offered 
his “pearls” of clinical wisdom 
on rounds and during morning 
As a high school student, 
Sudhakar Nuti came to 
Yale to learn anatomy 
from medical students. 
Last fall, he became 
the fi rst graduate of the 
Anatomy Teaching 
Program to enter Yale 
as a medical student.
Mary Bassett, M.D., 
M.P.H., New York City’s 
new health commissioner, 
talks about health in-
equities on the Depart-
ment of Internal Medi-
cine’s Global Health Day.
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 





he thanked his son Judd, a 1996 
graduate of Yale’s medical school, 
for “many fruitful discussions” as 
the book came together.
Released last September, 
the book has already started 
reaching its target audience. At 
Northwestern, the Department 
of Medicine distributed it to 
residents and faculty members. 
Internal medicine residency pro-
gram director Aashish Didwania, 
M.D., describes it as “extremely 
accessible and clinically relevant,” 
and containing pearls not easily 
found in textbooks. Chief medical 
resident Natasha Nichols, M.D., 
often uses Landsberg’s book after 
a heavy call day to look for teach-
ing points to discuss on rounds. 
While he doesn’t carry the 
book in his white coat, second-
year resident Andrew Davis, M.D., 
appreciates having Landsberg’s 
tried-and-true observations close 
at hand. “The book taps into how 
a master clinician thinks, which is 
one quality that makes it unique.”
—Cheryl SooHoo
report, but he never wrote them 
down—until recently. 
Prompted by colleagues and 
students, Landsberg spent a 
little over a year recalling from 
memory the many “pithy state-
ments of fact” now featured 
in the new book On Rounds: 
1000 Internal Medicine Pearls—
Clinical Aphorisms and Related 
Pathophysiology (Wolters Kluwer, 
2016). The pocket-sized book 
presents the pearls by organ 
system for easy reference, fea-
turing information Landsberg 
deemed most critical to develop-
ing mature clinical judgment. For 
example, a favorite Landsberg 
aphorism, “Never let a single lab-
oratory result dissuade you from 
a diagnosis strongly suggested by 
the weight of the clinical find-
ings,” reminds inexperienced-
to-seasoned clinicians not to rely 
solely on the numbers.
The book also includes a few 
faux pearls to keep readers on 
their toes. For example, a widely 
held belief is that antibiotics 
should be avoided in cases of 
Salmonella enteritis because 
treatment may result in a pro-
longed carrier state. Not true, 
according to Landsberg. “The 
point is to be aware,” he said. 
“Not everything people tell you 
is correct.”
A master clinician in his 
own right, Landsberg learned 
from the very best. A member of 
Beeson’s last internship group, 
known as the Iron 'Terns, the 
native New Yorker went on to 
become chief resident in medi-
cine at Yale-New Haven Hospital 
under the mentorship of Philip 
K. Bondy, M.D. Landsberg then 
completed a research fellow-
ship at the National Institutes 
of Health in the laboratory of 
Nobel laureate Julius Axelrod, 
Ph.D., before returning to Yale as 
a junior faculty member. In 1972, 
former Yale professor Franklin 
H. Epstein, M.D., moved on to 
Harvard Medical School and 
lured Landsberg away from his 
alma mater. During his 18-year 
tenure at Harvard, Landsberg 
served as chief of the Division of 
Endocrinology and Metabolism. 
Leaving Boston for Chicago in 
1990, he became chair of internal 
medicine at Northwestern and a 
decade later, dean.
In 2007, Landsberg stepped 
down from the top spot to launch 
the Northwestern Comprehensive 
Center on Obesity. Running the 
center has given him the oppor-
tunity to tackle the problem 
of obesity with novel clinical 
approaches and advancements in 
research, including his own. He 
has long conducted studies in the 
areas of catecholamines, dietary 
intake and the sympathetic ner-
vous system, and obesity and 
hypertension. It also has afforded 
him the time to return to teaching 
medical students and residents—
and sharing his pearls.
 Landsberg dedicated his book 
in part to his intern group at Yale, 
“whose friendship has been a life-
long treasure.” He also acknowl-
edged some of the many mentors 
who helped shaped his career, 
including Yale professors Beeson, 
Bondy, and Epstein. Additionally, 
Over the course of more than 50 years as 
a clinician, Lewis Landsberg has distilled 
his knowledge into aphorisms that he 
shared with younger doctors. Now he has 










Over the next decade, Lin establish-
ed training platforms and programs 
to help more than 40 labs launch 
research projects on human embry-
onic stem cells and induced pluri-
potent stem cells (iPSCs). He also 
recruited a handful of fast-rising 
stars to the center and recruited 
others to Yale. Now, Yale’s 91 stem 
cell researchers collaborate, trou-
bleshoot, and problem solve across 
the campus—not just within the 
brick walls of the center on Amistad 
Street. The center acts as a hub 
rather than a hierarchy, and that has 
encouraged spontaneity and cre-
ativity within research experiments, 
Lin said.
   How Haifan Lin  
 pushes the envelope  
  on stem cell research
As Lin recalled the center’s con-
tributions to stem cell science, he 
highlighted its breakthroughs in 
basic biology and innovations in 
translational science. In 2010, Time 
magazine featured lab-grown lungs 
created by Laura Niklason, Ph.D., 
M.D., the Nicholas Greene Professor 
of Anesthesiology and Biomedi-
cal Engineering, as No. 12 out of 
50 important inventions that year. 
(Apple’s iPad was No. 34 that year.) 
For Lin, who began researching 
stem cells in fruit flies as a postdoc 
at the Department of Embryology at 
the Carnegie Institution for Science 
in Baltimore Md., in the 1990s, the 
field has advanced at warp speed. 
“Using stem cells to cure diseases is 
not a promise of tomorrow, it has 
begun as a reality of today,” he said. 
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question and answer
WHEN HAIFAN LIN, PH.D., the Eugene Higgins Professor of Cell 
Biology and founding director of the Yale Stem Cell Center, 
arrived in New Haven in 2006, Dean Robert J. Alpern, M.D., 
Ensign Professor of Medicine, gave him a straightforward 
albeit Herculean mission: Build a top-notch stem cell 
research center. Lin took note of School of Medicine 
researchers whose experiments had already delved deep 
into stem cells, and asked them to join the center as affiliates.
{To nominate a subject for Q&A, contactYale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu





nucleotides that make up a 
gene are beads on a necklace. 
Most genes make RNAs that 
are 1,000 beads (nucleotides) 
or longer. But these genes 
make tiny RNAs that have 
only 24 to 31. These genes 
are located in the part of the 
genome that used to be called 
junk DNA. People thought 
they had no purpose, but I 
believed they existed for a rea-
son. The latest research from 
my lab suggests that these 
RNA-making genes could 
be closely related to cancer. 
Normally, these genes are 
expressed only in reproduc-
tive cells (egg or sperm). But 
we found that regular cells in 
the body, called somatic cells, 
become cancerous when some 
of these genes are expressed. 
We have preliminary evidence 
to show that if you remove 
the expression of these genes, 
then it may be possible to slow 
down cancer development.
Many universities and col-
leges have stem cell research 
centers. How is Yale’s dif-
ferent? Many stem cell 
centers are heavily focused 
on the translational side. 
This strategy has its reasons 
and strengths. However, we 
started by exploring the basic 
science to better understand 
what is going on behind the 
development and biology of 
stem cells because the inner 
working mechanisms of stem 
a person who favors a conser-
vative approach to stem cell 
research does not have a prob-
lem turning his or her own 
ordinary cells, such as skin 
cells, into stem cells for treat-
ment. The second advantage is 
that iPS cells from a person’s 
body can become various 
types of tissue cells that will 
be recognized by our immune 
system as our own cells, and 
so you do not have to worry 
about our bodies rejecting 
them after transplanta-
tion. The third is that we can 
now obtain all types of cells 
from our iPS cells instead of 
directly from our body, which 
is often impossible. This way 
we can study the causes of 
diseases in our tissue cells and 
try out different treatments 
without using or hurting our 
bodies. 
Stem cells exist through-
out the human body in all 
organs and tissue, but are 
rare and difficult to find. Why 
is that? Because they are 
the most important cells, so 
they exist in extremely small 
numbers and often hide in the 
most protected locales. Like 
on a battlefield, the soldiers, 
or regular cells, are on the 
frontline. But the commander, 
or stem cell, is hiding, usually 
toward the back, in a fortified 
shelter. That’s why we’ve had 
to use special methods in the 
lab to identify stem cells.
What aspect of stem cell 
basic science research 
excites you most right now?  
We are exploring new ter-
ritory within the molecular 
mechanisms that govern stem 
cell division. For example, 
Andrew Zhuo Xiao, Ph.D., 
assistant professor of genet-
ics, recently discovered a 
new modification of the DNA 
structure as a mechanism of 
gene regulation. DNA car-
ries genetic information, but 
there are molecules modify-
ing DNA to determine which 
genes are active or inactive. 
Xiao found this new kind of 
modification to be important 
for embryonic stem cells. He 
also discovered a specific pro-
tein responsible for regulating 
this modification of DNA. If a 
stem cell lacks the modifica-
tion, then its fate will change. 
Researchers didn’t know 
this form of gene regulation 
existed in stem cells or any 
mammalian cells. This is one 
example of how we are push-
ing the envelope of knowledge 
not only on stem cells, but 
also on basic biology. 
Tell us about your own 
research. In one area of my 
research, I focus on under-
standing a new class of genes 
that produce tiny RNAs 
instead of proteins. In my lab, 
we have cloned over 10 mil-
lion tiny RNAs, a number 
that is about 400 times more 
than the total known number 
of genes. Imagine that the 
cells are still poorly under-
stood. Our strategy is to start 
by discovering more about 
the fundamental principles 
and theories around stem 
cells, and then apply this new 
knowledge to translational 
and clinical research.
Bone marrow transplants 
were for a long time the only 
stem cell therapy approved 
by the Food and Drug 
Administration. Why don’t 
we have more approved 
therapies? Several other stem 
cell-related therapies have 
recently been approved by 
the FDA for clinical trial. For 
example, Yale-New Haven 
Hospital has the first FDA-
approved clinical trial for 
a bone marrow cell-based 
therapy for congenital heart 
defects, which has been very 
successful. These new approv-
als reflect the rapid progress of 
the field. We are still working 
on the best and most reliable 
methods for growing millions 
of stem cells outside the body 
for therapeutic purposes. A 
stem cell transplant requires 
many cells—just isolating the 
cells is not enough. We also 
need to find a way to amplify 
stem cells without changing 
their properties.
Why was Shinya Yamanaka’s 
discovery of induced pluripo-
tent stem (iPS) cells in Japan 
in 2006 so important?  
It offered three huge advan-















  Hair and the  
course of human history
 By Cathy Shufro
The hair on our heads is just 
the departure point for this 
wide-ranging book by Kurt 
Stenn, M.D. The former Yale 
pathologist and dermatolo-
gist moves from the evolu-
tion of human hair to hair’s 
effects on culture, psychol-
ogy, and global trade. By 
the end of Hair: A Human 
History, a reader might 
even be convinced that hair 
makes the world go ’round.
Stenn begins by explain-
ing why we, of all primates, 
lost most of our body hair: 
Our ancestors became naked 
apes to cool their growing 
and temperature-sensitive 
brains, which would suffer 
a meltdown (that is, brain 
death) at 107 degrees 
Fahrenheit. Just 10 or 20 min-
utes of walking, scientists 
have estimated, would have 
felled upright fur-covered 
hominids with heatstroke. 
Unlike animal hair, which 
grows on a fixed cycle and 
sheds twice a year, human 
hair follicles stagger their 
growth. Moreover, each type 
of human hair abides by its 
own calendar. A scalp hair 
shaft will grow for two to 
six years, allowing humans 
to wear hair cascading down 
their backs or in coronas 
around their heads. Eyelashes 
remain short because they 
grow for just 30 days.
Another mammal’s 
hair—sheep’s wool—shaped 
Western culture. English 
herders raised the best 
wool, and competed with 
Flanders to turn it into 
cloth for the world. The 
wool trade created the for-
tunes of such bankers as the 
Florentines, whose patron-
age of Michelangelo gave us 
the Sistine Chapel's painted 
ceiling. The descendant of 
an English wool merchant 
named John Barton placed 
a sign in the window of 
his “fair stone house” that 
exulted, “I thank God and 
ever shall/It is the sheepe 
hath payed for all.” 
The hair of the beaver 
also changed the course of 
history. By the 16th century, 
beaver-felt hats were all 
the rage in Europe. Hatters 
who used toxic mercury in 
the felting process devel-
oped dementia—thus, the 
expression “mad as a hatter.” 
Nonetheless, “everyone who 
was anyone” wanted a beaver 
hat, Stenn writes. When the 
fashion killed off beavers  
in European forests, traders  
sailed to North America, 
where Native Americans 
bartered pelts for pots, guns, 
rum, and metal beaver traps. 
By about 1840, the trade had 
ravaged the North American 
beaver population as well. 
Animal hair does more 
than keep us warm and 
stylish. Bow makers, called 
archetiers, use horsehair and 
rosin to create the ribbon on a 
violin or cello bow. (Stallions 
from cold climates provide the 
best bow hair.) Percussionists 
strike drums using hammers 
cushioned with sheep’s wool 
felt. Paint brushes contain 
hair from pigs, squirrels, bad-
gers, and cows. 
Research into hair could 
help solve fundamental sci-
entific problems, Stenn says. 
For instance, scientists do not 
fully understand what causes 
stem cells in the mid-follicle 
to differentiate into hair shaft 
cells. “If we understood the 
hair follicle,” says Stenn, “we 
would probably get a good 
understanding of the regen-
eration process of the lung 
and the kidney and the eye. 
Biology is so conserved that 
the law of one organ system 
is very related to the law of 
another system.”
During two years of 
research, Stenn visited wig-
makers in Japan, studied 
the anthropology of hair in 
Paris, learned about furs in 
Montreal, and toured a wool 
museum in Wales. Stenn, on 
the faculty at the School of 
Medicine from 1971 to 1991 
and the former director of 
skin biology at Johnson & 
Johnson, now writes full time. 
Next, he plans an illustrated 
children’s book on hair. “I’ll 
still keep the science in,” says 
Stenn. He may use dogs and 
cats to demonstrate that fur 
is directional. “You don’t pet 
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book review
E L E V E N C OU PL E S, including physicians, 
transplant nurses, an organ recipient, and donor 
advocates, danced away the night of March 
18 at the Aria Banquet Facility in Prospect to 
raise awareness of organ donation in a time 
of organ shortages. More than 500 people at 
the Dancing for Donation Gala, sponsored 
by Donate Life Connecticut, watched danc-
ers including Yale’s own Joyce Alpert, Manuel 
Rodriguez and Patricia Aguayo, Bill and Christy 
Asch, Gary and Deborah Desir (in photo), and 
Frank and Margaret Bia, perform ballroom rou-
tines. Donations made on behalf of the teams 
raised more than $45,000.  e event’s grand 
champions, Rodriguez and Aguayo, raised more 
than $10,000.  e Desirs won fi rst place in tal-
ent, and the Bias took second place.
—John Curtis
Dancing for Donation
Send notices of new books to
Yale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
end note
